VRTX | tickerfilter.com

Fundamental analysis

46%

Profitability 67%

Dept financing 7%

Liquidity 62%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-15.34%

1 Month

-11.91%

3 Months

-13.64%

6 Months

-16.36%

1 Year

-1.97%

2 Year

35.16%

Key data

Stock price

$474.16

P/E Ratio

-261.26

DAY RANGE

$395.50 - $474.16

EPS

-$1.88

52 WEEK RANGE

$396.14 - $519.88

52 WEEK CHANGE

-$1.97

MARKET CAP

127.990 B

YIELD

N/A

SHARES OUTSTANDING

258.102 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/04/2024

BETA

0.57

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,006,381

AVERAGE 30 VOLUME

$1,821,000

Company detail

CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.

VRTX - VERTEX PHARMACEUTICALS INC / MA